Navigation Links
AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
Date:10/1/2008

Japan through Shionogi.

In addition to the Phase 3 program in BPH, cetrorelix is also being studied in a Phase 2b program in this same indication in Japan, sponsored by the Company's partner, Shionogi.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at http://www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
2. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
3. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
4. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
5. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
6. AEterna Zentaris Sells Quebec City Building for $7.1 million
7. AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
8. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
9. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
10. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
11. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 Philadelphia’s newest entrepreneurial incubation space ... their start. The Innovation Center @3401 , a collaborative ... City Science Center to help attract and nurture start-up ... July 28. , The Innovation Center @3401 ... Market Streets, is the new home of DreamIt Ventures ...
(Date:7/29/2014)... -- United Therapeutics Corporation (NASDAQ: UTHR ... the second quarter ended June 30, 2014. ... medicines are reaching increasing numbers of patients ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and ... quarter of our extended-release tablet called Orenitram ...
(Date:7/29/2014)... Wendel – recipient of a Regional Top Doctor Award for ... Surgeon Specialists for Nashville, TN – has released a new ... Hydration Booster, Retexturing Night Crème, and Anti-aging C Complex, all ... radiant appearance while protecting them from the sun’s harmful UV ... Dr. J. J. Wendel Plastic Surgery, we have developed a ...
(Date:7/28/2014)... July 28, 2014 Sapphire Energy, Inc. ... announced the appointment of biotechnology veteran James Levine ... of directors. Levine replaces Cynthia ,CJ, Warner, who is ... remain chairman of the company,s board of directors. ... mission to deliver commercial scale algae-based fuels has been ...
Breaking Biology Technology:Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13Dr. J. J. Wendel Launches New Line of Skin Care Products 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3
... like when it was a baby. They know what it ... looked in its youth. Thanks to technological advances, however, scientists ... of how the cosmos developed into the kind of place ... They plan to gather these never-before-obtained insights with a potentially ...
... BOTHELL, Wash., June 30, 2011 SCOLR Pharma, Inc. ... second and final tranche of its previously-announced private placement ... (the "Debentures").  The Company raised a total of $1,190,200 ... net proceeds for working capital and other general corporate ...
... OXIS International, Inc. (OTC Bulletin Board: OXIS ; ... Saloff to its Board of Directors.  The Company,s Board now ... are very pleased to have David Saloff, an outstanding businessmen ... said Anthony J. Cataldo, Chairman of OXIS International. "OXIS is ...
Cached Biology Technology:Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 2Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 3Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 4SCOLR Pharma, Inc. Announces Final Closing of Private Placement 2SCOLR Pharma, Inc. Announces Final Closing of Private Placement 3OXIS International Names Healthcare Industry Entrepreneur David Saloff to Board of Directors 2OXIS International Names Healthcare Industry Entrepreneur David Saloff to Board of Directors 3
(Date:7/28/2014)... 100 drugs already approved by the U.S. Food and ... the growth of certain bacterial pathogens inside human cells, ... spotted fever. The findings, published in mBio , ... Microbiology, demonstrate a new way of identifying non-antibiotic drugs ... , A handful of drugs on the list inhibit ...
(Date:7/28/2014)... reached the South Pole in 1911, but new research ... human. , Using data from 16 ice cores collected ... the South Pole, a group led by Joe McConnell ... created the most accurate and precise reconstruction to date ... record, described in an article published today in the ...
(Date:7/28/2014)... in the United States have a circulatory problem of ... painful and may even require surgery in serious cases. ... and, in turn, limb amputation. , At The University ... School, scientists tested a non-surgical preventative treatment in a ... with increased blood circulation. Their proof-of-concept study appears ...
Breaking Biology News(10 mins):New route to identify drugs that can fight bacterial infections 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
... American Academy of Pediatrics National Children,s Art Contest drew hundreds ... With the theme of "My Healthy Lifestyle," the 2011 ... obesity, diet, exercise, sleep and limiting screen time. This was ... of the three age groups each receive a $500 cash ...
... grown apple may hold within it a tiny bit of ... teamed up on a startup that promises to turn slash ... for farmers that helps their soil hold water and nutrients. ... for farmers. "Wine growers, organic farmers and gardeners of all ...
... generally considered to be a good thing for people ... too risky for women who are also pregnant. Some ... the risk of women developing preeclampsia, a condition that ... this might happen has remained unknown. New research using ...
Cached Biology News:Turning slash piles into soil benefit 2Exercise before and during early pregnancy increases two beneficial proteins for mothers-to-be 2